Showing results (11-20 of 55) with videos related to
Sort By:
Pageof 6
Cancer Research|November 21, 2024
Cancer-Related Cognitive Impairment and the Potential of Dietary Interventions for the Prevention and Mitigation of NeurodegenerationSylvia L Crowder, Lisa M Gudenkauf, Aasha I Hoogland, et al.Journal of Neuro-Oncology|July 25, 2023
Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastasesVaseem M Khatri, Matthew N Mills, Daniel E Oliver, et al.Patient Education and Counseling|September 9, 2020
Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplarSuzanne C O'Neill, Susan T Vadaparampil, Richard L Street, et al.Journal for Immunotherapy of Cancer|June 16, 2022
Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinomaGanesan Ramamoorthi, Krithika Kodumudi, Colin Snyder, et al.Oncology|August 4, 2025
A real-world single-center cohort study on the tolerability of trastuzumab deruxtecan for HER2+ metastatic breast cancerAmeer Basta, Kyle Lien, Weihong Sun, et al.The Lancet. Oncology|March 28, 2024
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b studyRachel M Layman, Hyo S Han, Hope S Rugo, et al.Breast Cancer Research and Treatment|February 8, 2020
Management of brain metastases in breast cancer: a review of current practices and emerging treatmentsMatthew N Mills, Nicholas B Figura, John A Arrington, et al.Journal for Immunotherapy of Cancer|January 6, 2026
Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancerAixa Soyano, Marie Catherine Lee, Hyo S Han, et al.Therapeutic Advances in Medical Oncology|December 17, 2021
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i>/<i>2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trialJean-Pierre Ayoub, Hans Wildiers, Michael Friedlander, et al.Biorxiv : the Preprint Server for Biology|June 12, 2026
Ploidy shapes gemcitabine response through altered potency and delayed cell deathVural Tagal, Tao Li, Rikhil Kumar, et al.Pageof 6